October 17, 2025Current OncologyOpen Access

Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence

View Full Paper

Ask AI

Bookmark

Authors

FCF.J. Muñoz i CarrilloBreast Cancer Research Foundation RRRoxana ReyesInstituto Oncológico Dr. Rosell DPDavid PesántezBreast Cancer Research Foundation

Discussion

Member takes

Implication

Retrospective cohort study assessed IPIC effects on malignant pericardial effusion recurrence in cancer patients, implying potential benefits in clinical settings.

Key Points

IPIC reduced malignant pericardial effusion recurrence, showing positive outcomes in patients with cancer.
Among 41 patients, those receiving IPIC demonstrated a median survival of 161 days from MPE diagnosis.
Adverse events occurred in 24% of patients, mainly transient atrial fibrillation, indicating manageable side effects.
Non-small cell lung cancer was the primary diagnosis in 78% of participants, highlighting its prevalence in this condition.

Cite This Study

Carrillo et al. (2025) studied this question.

synapsesocial.com/papers/68f199b7de32064e504dc633 https://doi.org/10.3390/curroncol32100568

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study assessed IPIC effects on malignant pericardial effusion recurrence in cancer patients, implying potential benefits in clinical settings.

Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence

Discussion

Member takes

Implication

Key Points

Cite This Study

Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider